TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
NextCell Pharma AB
Closing information (x1000 EUR)
| Closing information | 2024/08 | 2023/08 | 2022/08 |
| Turnover |
854
|
523 | |
| Financial expenses |
0
|
1 | |
| Earnings before taxes |
-3,362
|
-3,235 | |
| EBITDA |
-3,424
|
-3,236 | |
| Total assets |
7,500
|
11,669 | |
| Current assets |
5,680
|
9,994 | |
| Current liabilities |
851
|
649 | |
| Equity capital |
6,394
|
10,816 | |
| - share capital |
595
|
660 | |
| Employees (average) |
24
|
17
|
15 |
Financial ratios
| Fiscal year | 2024/08 | 2023/08 | 2022/08 |
| Solvency |
85.3%
|
92.7% | |
| Turnover per employee |
50
|
35 | |
| Profit as a percentage of turnover |
-393.7%
|
-618.5% | |
| Return on assets (ROA) |
-44.8%
|
-27.7% | |
| Current ratio |
667.5%
|
1539.9% | |
| Return on equity (ROE) |
-52.6%
|
-29.9% | |
| Change turnover |
382
|
157 | |
| Change turnover % |
5%
|
81%
|
43% |
| Chg. No. of employees |
7
|
2
|
2 |
| Chg. No. of employees % |
41%
|
13%
|
15% |
Total value of public sale
| Fiscal year | 2024/08 | 2023/08 | 2022/08 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.